Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 3, 2013

Enanta Gets Additional $9.2M toward Biodefense Antibiotic Development

  • The National Institute of Allergy and Infectious Diseases (NIAID) is providing additional funding of $9.2 million to its existing contract with Enanta Pharmaceuticals to fund preclinical and early clinical development for a new class of bridged bicyclic antibiotics called bicyclolides. This brings total funding from NIAID to date to approximately $23.5 million.

    NIAID is funding development of the bicyclolides for use as medical countermeasures against multiple biodefense Category A and B bacteria including anthrax, plague, and tularemia. As part of a multi-year contract that was awarded in 2011, this funding could total approximately $42.7 million if all project milestones are met and if NIAID exercises all its options to fund additional development under the contract.

    Enanta says that bicyclolides are very effective against resistant pathogens because of a unique binding site on the bacterial ribosome. In addition to the NIAID contract, Enanta is focused on the potential use of their lead bicyclolide antibiotic candidate EDP-788 for the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and drug-resistant streptococci. All preclinical and early clinical development of EDP-788 is funded under Enanta’s contract with NIAID. Initiation of clinical trials is planned for the first half of 2014.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »